OncoMatch/Liver Cancer (HCC)/PD-L1 (CD274)
Liver Cancer (HCC)PD-L1 (CD274) Clinical Trials
PD-L1 expression informs but does not strictly gate immunotherapy eligibility in HCC: atezolizumab plus bevacizumab and durvalumab plus tremelimumab are first-line approved regardless of PD-L1. PD-L1 TPS and CPS are assessed in many trials as a biomarker correlation endpoint. Trials investigate novel checkpoint combinations, IO plus VEGF/TKI regimens, and neoadjuvant immunotherapy strategies in early-stage resectable HCC.
Top recruiting PD-L1 (CD274) Liver Cancer (HCC) trials
Ranked by phase and US site count. See all 8 trials matched to your profile →
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Shanghai Henlius Biotech
A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
Shanghai Henlius Biotech
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
National University Hospital, Singapore
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
Hefei TG ImmunoPharma Co., Ltd.
Browse other molecular targets with active Liver Cancer (HCC) trials.